Is Lexicon Pharmaceuticals Stock a Good Investment?
Lexicon Pharmaceuticals Investment Advice | LXRX |
- Examine Lexicon Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Lexicon Pharmaceuticals' leadership team and their track record. Good management can help Lexicon Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Lexicon Pharmaceuticals' business and its evolving consumer preferences.
- Compare Lexicon Pharmaceuticals' performance and market position to its competitors. Analyze how Lexicon Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Lexicon Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Lexicon Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Lexicon Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Lexicon Pharmaceuticals is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Lexicon Pharmaceuticals Stock
Researching Lexicon Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 82.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.63. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Lexicon Pharmaceuticals recorded a loss per share of 0.74. The entity had not issued any dividends in recent years. The firm had 1:7 split on the 21st of May 2015.
To determine if Lexicon Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Lexicon Pharmaceuticals' research are outlined below:
| Lexicon Pharmaceuticals generated a negative expected return over the last 90 days | |
| Lexicon Pharmaceuticals has high historical volatility and very poor performance | |
| Lexicon Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Lexicon Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 1.2 M. Net Loss for the year was (177.12 M) with loss before overhead, payroll, taxes, and interest of (52.68 M). | |
| Lexicon Pharmaceuticals currently holds about 61.97 M in cash with (161.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.34. | |
| Over 82.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic ... |
Lexicon Pharmaceuticals Quarterly Cash And Short Term Investments |
|
Lexicon Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Lexicon Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Lexicon Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Lexicon Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Lexicon Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-06 | 2024-09-30 | -0.16 | -0.18 | -0.02 | 12 | ||
2024-08-01 | 2024-06-30 | -0.19 | -0.17 | 0.02 | 10 | ||
2021-11-03 | 2021-09-30 | -0.18 | -0.16 | 0.02 | 11 | ||
2023-03-02 | 2022-12-31 | -0.13 | -0.16 | -0.03 | 23 | ||
2021-07-30 | 2021-06-30 | -0.16 | -0.13 | 0.03 | 18 | ||
2016-05-03 | 2016-03-31 | -0.3 | -0.34 | -0.04 | 13 | ||
2023-08-03 | 2023-06-30 | -0.17 | -0.22 | -0.05 | 29 | ||
2018-05-03 | 2018-03-31 | -0.45 | -0.4 | 0.05 | 11 |
Know Lexicon Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Lexicon Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Lexicon Pharmaceuticals backward and forwards among themselves. Lexicon Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Lexicon Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Pinnacle Associates Inc | 2024-09-30 | 1.7 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1.4 M | Point72 Asset Management, L.p. | 2024-09-30 | 1.2 M | Marshall Wace Asset Management Ltd | 2024-06-30 | 1.2 M | Northern Trust Corp | 2024-09-30 | 1.1 M | Braidwell Lp | 2024-09-30 | 801.6 K | Wellington Management Company Llp | 2024-06-30 | 738.6 K | Hennion & Walsh Asset Management Inc | 2024-09-30 | 731.1 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 708.1 K | Artal Group S A | 2024-06-30 | 175.1 M | Fmr Inc | 2024-09-30 | 49.9 M |
Lexicon Pharmaceuticals' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 290.96 M.Market Cap |
|
Lexicon Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.96) | (0.91) | |
| Return On Capital Employed | (0.87) | (0.82) | |
| Return On Assets | (0.77) | (0.73) | |
| Return On Equity | (1.90) | (1.81) |
Determining Lexicon Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Lexicon Pharmaceuticals is a good buy. For example, gross profit margin measures Lexicon Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Lexicon Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Lexicon Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Lexicon Pharmaceuticals. Check Lexicon Pharmaceuticals' Beneish M Score to see the likelihood of Lexicon Pharmaceuticals' management manipulating its earnings.
Evaluate Lexicon Pharmaceuticals' management efficiency
Lexicon Pharmaceuticals has return on total asset (ROA) of (0.4416) % which means that it has lost $0.4416 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3609) %, meaning that it created substantial loss on money invested by shareholders. Lexicon Pharmaceuticals' management efficiency ratios could be used to measure how well Lexicon Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -0.91 in 2024. Return On Capital Employed is likely to rise to -0.82 in 2024. At this time, Lexicon Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 104.9 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 786.6 K in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.42 | 0.40 | |
| Tangible Book Value Per Share | 0.22 | 0.21 | |
| Enterprise Value Over EBITDA | (2.58) | (2.71) | |
| Price Book Value Ratio | 3.63 | 5.52 | |
| Enterprise Value Multiple | (2.58) | (2.71) | |
| Price Fair Value | 3.63 | 5.52 | |
| Enterprise Value | 708.4 M | 363.8 M |
The strategic initiatives led by Lexicon Pharmaceuticals' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Beta 1.244 |
Basic technical analysis of Lexicon Stock
As of the 29th of November, Lexicon Pharmaceuticals secures the Standard Deviation of 6.12, mean deviation of 3.69, and Risk Adjusted Performance of (0.11). In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Lexicon Pharmaceuticals, as well as the relationship between them.Lexicon Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lexicon Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lexicon Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Lexicon Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Lexicon Pharmaceuticals' Outstanding Corporate Bonds
Lexicon Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Lexicon Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Lexicon bonds can be classified according to their maturity, which is the date when Lexicon Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Understand Lexicon Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Lexicon Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.11) | |||
| Market Risk Adjusted Performance | (0.83) | |||
| Mean Deviation | 3.69 | |||
| Coefficient Of Variation | (656.06) | |||
| Standard Deviation | 6.12 | |||
| Variance | 37.5 | |||
| Information Ratio | (0.17) | |||
| Jensen Alpha | (1.07) | |||
| Total Risk Alpha | (1.87) | |||
| Treynor Ratio | (0.84) | |||
| Maximum Drawdown | 46.58 | |||
| Value At Risk | (7.55) | |||
| Potential Upside | 6.7 | |||
| Skewness | (3.14) | |||
| Kurtosis | 18.92 |
| Risk Adjusted Performance | (0.11) | |||
| Market Risk Adjusted Performance | (0.83) | |||
| Mean Deviation | 3.69 | |||
| Coefficient Of Variation | (656.06) | |||
| Standard Deviation | 6.12 | |||
| Variance | 37.5 | |||
| Information Ratio | (0.17) | |||
| Jensen Alpha | (1.07) | |||
| Total Risk Alpha | (1.87) | |||
| Treynor Ratio | (0.84) | |||
| Maximum Drawdown | 46.58 | |||
| Value At Risk | (7.55) | |||
| Potential Upside | 6.7 | |||
| Skewness | (3.14) | |||
| Kurtosis | 18.92 |
Consider Lexicon Pharmaceuticals' intraday indicators
Lexicon Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Lexicon Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Lexicon Pharmaceuticals time-series forecasting models is one of many Lexicon Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Lexicon Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Lexicon Stock media impact
Far too much social signal, news, headlines, and media speculation about Lexicon Pharmaceuticals that are available to investors today. That information is available publicly through Lexicon media outlets and privately through word of mouth or via Lexicon internal channels. However, regardless of the origin, that massive amount of Lexicon data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Lexicon Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Lexicon Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Lexicon Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Lexicon Pharmaceuticals alpha.
Lexicon Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Lexicon Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Lexicon Pharmaceuticals Corporate Management
| Kenneth MD | Senior Assurance | Profile | |
| Chas Schultz | Executive Advocacy | Profile | |
| Robert MD | Consultant Director | Profile | |
| Tom Garner | Senior Officer | Profile | |
| Desiree Gendron | Vice Training | Profile |
Additional Tools for Lexicon Stock Analysis
When running Lexicon Pharmaceuticals' price analysis, check to measure Lexicon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceuticals is operating at the current time. Most of Lexicon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexicon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lexicon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.